Días clave para el proceso de venta de la farmacéutica portuguesa Generis. El fondo español Magnum Capital Industrial Partners, que controla la empresa de productos genéricos desde 2009, tiene media docena de ofertas iniciales de compra sobre la mesa y confía en poder materializar el traspaso antes de julio, indican fuentes del mercado.
Después de que Pfizer no consiguiese cerrar la compra Allergan, la compañía ha anunciado que comprará la farmacéutica Anacor Pharamaceuticals por 5.200 millones de dólares en efectivo (unos 4.600 millones de euros), según ha informado la propia Pfizer en un comunicado. Las acciones de Anacor, se disparan.
Back in Thomas Edison’s day, Americans could pick out a Sears Modern Home from a mail-order catalog and have it shipped to their new address for assembly. “Not only did precut and fitted materials shrink construction time up to 40 percent, but Sears’s use of ‘balloon style’ framing, drywall, and asphalt shingles greatly eased construction for homebuyers,” the company boasted. Now GE Healthcare has taken a page from the same book and delivers an entire high-tech pharmaceuticals factory — walls and all.
The latest biopharmaceutical company testing Wall Street’s belief in the promise of gene modification has gone public. Intellia Therapeutics (NASDAQ: NTLA) of Cambridge, MA, which owns rights to an important but disputed piece of the CRISPR-Cas9 gene editing technology, sold 6 million shares at $18 each this evening to raise $108 million. Its stock will trade on the Nasdaq starting tomorrow under the ticker “NTLA.”
The pricing is a 27 percent bump over Intellia’s goal last week of selling 5 million shares in the $16 to $18 range. It does not include another $55 million Intellia planned to sell separately to two drug-development partners.
The most expensive drug in history is a money loser that’s not reaching patients. In fact, it’s only been paid for and used commercially once since being approved in 2012.
The medication in question is alipogene tiparvovec, better known as Glybera, a medicine widely heralded as the “first gene therapy” in the Western world and whose approval helped ignite an explosion of investment and excitement around treatments that correct DNA.
Last year’s shakeup and mea culpa at San Diego’s Acadia Pharmaceuticals (NASDAQ: ACAD) has paid off. The FDA said late today it has approved Acadia’s pimavanserin (Nuplazid), a treatment for psychosis associated with Parkinson’s disease.
The next generation of vaccines may soon see the light of day, because Danish researchers have discovered a completely new and simple method which sets new standards for the development of vaccines.
"The major research breakthrough is that we have created a general and user-friendly platform for the development of a special type of effective and safe vaccines. The highly effective method opens a new door for controlling diseases such as cancer, asthma, allergies and cardiovascular diseases by means of vaccines. We are therefore already now able to initiate strategies to combat some of the biggest killers in the western world," says Postdoc Adam Sander, Department of Immunology and Microbiology, University of Copenhagen.
La compañía de tecnología sanitaria Abbott ha llegado a un acuerdo para adquirir St. Jude Medical, una empresa de dispositivos médicos, por 25.000 millones de dólares (22.035 millones), informa Reuters.
Los accionistas de St. Jude recibirán 85 dólares por acción, de los que 46,75 dólares serán en efectivo y el resto en títulos. La oferta representa un 37% de prima respecto al cierre de cotización de la adquirida en la sesión del miércoles. El acuerdo supondría 0,21 euros de ingresos por acción, según la empresa.
Second Genome, a South San Francisco, CA-based biotech using microbiome research to develop traditional small-molecule drugs, has tapped an unusual group of private investors for nearly $43 million in a Series B round of financing.
The cash should take Second Genome through a Phase 2 trial for its lead drug, aimed at ulcerative colitis, and help turn its microbiome research capabilities into more drugs, said CEO Peter DiLaura.
El omeprazol es el fármaco genérico más prescrito en España, con más de 54 millones de envases vendidos en 2013 según datos del propio Ministerio de Sanidad. Sin embargo, hace algún tiempo que los médicos vienen alertando del alegre consumo que se hace de este medicamento que no está exento de riesgos. La última de estas advertencias procede de un trabajo estadounidense que relaciona su consumo a largo plazo con problemas serios de riñón.
